Pharma news daily

Here are some recent pharma news updates:

1. Pfizer's COVID-19 Vaccine Shows 95% Efficacy in Phase 3 Trial

Pfizer and BioNTech announced that their COVID-19 vaccine candidate, BNT162b2, has shown 95% efficacy in preventing severe illness and hospitalization due to COVID-19 in a Phase 3 clinical trial. The vaccine is expected to be submitted for emergency use authorization in the coming weeks. (Source: Pfizer)

2. Novartis Acquires The Medicines Company for $9.7 Billion

Novartis has agreed to acquire The Medicines Company, a biopharmaceutical company focused on cardiovascular and infectious diseases, for $9.7 billion. The deal is expected to strengthen Novartis' pipeline and expand its presence in the cardiovascular and infectious disease markets. (Source: Novartis)

3. FDA Approves AstraZeneca's Lynparza for BRCA-Mutated Breast Cancer

The FDA has approved AstraZeneca's Lynparza (olaparib) for the treatment of BRCA-mutated, HER2-negative advanced breast cancer. Lynparza is the first PARP inhibitor to receive FDA approval for this indication. (Source: AstraZeneca)

4. Gilead Sciences to Acquire Immunomedics for $21 Billion

Gilead Sciences has agreed to acquire Immunomedics, a biopharmaceutical company focused on oncology and autoimmune diseases, for $21 billion. The deal is expected to expand Gilead's presence in the oncology market and add Immunomedics' lead candidate, sacituzumab govitecan, to its pipeline. (Source: Gilead Sciences)

5. Johnson & Johnson's COVID-19 Vaccine Candidate Shows 72% Efficacy in Phase 3 Trial

Johnson & Johnson announced that its COVID-19 vaccine candidate, Ad26.COV2.S, has shown 72% efficacy in preventing severe illness and hospitalization due to COVID-19 in a Phase 3 clinical trial. The vaccine is expected to be submitted for emergency use authorization in the coming weeks. (Source: Johnson & Johnson)

6. Biogen and Eisai's Aducanumab Receives FDA Approval for Alzheimer's Disease

The FDA has approved Biogen and Eisai's aducanumab, a monoclonal antibody, for the treatment of Alzheimer's disease. Aducanumab is the first FDA-approved treatment to target amyloid beta, a protein believed to contribute to the progression of Alzheimer's disease. (Source: Biogen)

7. Merck & Co. to Acquire Pandion Therapeutics for $1.1 Billion

Merck & Co. has agreed to acquire Pandion Therapeutics, a biopharmaceutical company focused on autoimmune diseases, for $1.1 billion. The deal is expected to expand Merck's presence in the autoimmune disease market and add Pandion's lead candidate, PTX-022, to its pipeline. (Source: Merck & Co.)

These are just a few of the latest pharma news updates. Stay tuned for more updates on the latest developments in the pharmaceutical industry!